Save $50 and take a deep dive into your pups genetics with this dog DNA test – Yahoo News

The Daily Beast

A Delaware teenager has been charged with murder after allegedly luring her classmate into the woods and beating her to death alongside the girls ex-boyfriend, prosecutors said.Annika Stalczynski, 17, was arrested on Monday after a New Castle County grand jury indicted her on several chargesincluding first-degree murder, possession of a deadly weapon during commission of a felony, and conspiracyfor Madison Sparrows Oct. 2 slaying, according to the Delaware Attorney Generals office. Prosecutors allege Stalczynski, along with Sparrows ex-boyfriend, 19-year-old Noah Sharp, conspired to lure the teenager to the woods behind Maclary Elementary School, before they ambushed and fatally beat her with a metal baseball bat.The grand jury also indicted Sharp, who was arrested a few days after Sparrows death, on the same charges. The teenagers are in custody on $1 million bail.Utah Man Dies in Car Crash After Confessing He Killed His Wife: AuthoritiesEvery murder is an outrage, but the murder of a child strikes at everything we hold dear, Attorney General Kathy Jennings said in a statement. Madison was stolen from her family and friends with her life and her dreams still ahead of her. A life has been taken and a cruel trauma has been inflicted on hundreds of people who knew and loved this kind, gentle young woman.My heart aches for Madis parents, the Sparrow family, and the entire Newark Charter community. We can never replace what these people have lost, but we canand willhold her killers accountable, she added.According to court documents, prosecutors allege Sparrow, a junior at Newark Charter School, was reported missing by her mother at around 8:30 p.m. on Oct. 2 after she did not return from a trip to the store with a girlfriend.Another Fort Hood Soldier Has Been Arrested for Murder: AuthoritiesThe following day, police issued a Gold Alert for Sparrowa notification thats typically sent out when a senior citizen, suicidal person, or a person with a disability has gone missing. Investigators also spoke to friends and family, who revealed the 17-year-old had gone to an area in Newark where her ex-boyfriend Noah, was located.When authorities went to the wooded area, which was located behind Maclary Elementary School, they found an aluminum baseball bat, droplets of blood, and Sparrows clothing, according to court documents.Prosecutors state Sharp used the bat to fatally beat Sparrow to deathand that Stalczynski had planned the murder with the 19-year-old. An autopsy report confirmed Sparrow died of blunt force trauma to the head.It is not immediately clear why Stalczynski assisted Sharp in the grisly crime. But according to State Prosecutor A.J. Roop, Stalczynski and Sparrow were classmates at the Newark high school and had "known each other for some time."I believe that they had a relationship going back over a number of years, Roop said, according to Delaware Online. I won't get into much more than that, or what the status was recently, but they were acquaintances, and they did know each other.When investigators questioned Sharp on Oct. 5, following his arrest, the 19-year-old admitted he murdered his ex-girlfriendconfirming he used the bat to commit the crime, court documents state. Sharp added that after killing Sparrow, he moved her body to another wooded area about 20 minutes away from the elementary school off Route 896. Hours later, authorities found her body.Grand Jury Declines to Charge Officer Who Killed 21-Year-Old Dreasjon ReedSparrows death was met with an outcry of support online, where hundreds sent their condolences and shared stories about the 17-year-old and her family. Two vigils were also held in her honorone in New Jersey and one at her high schoolwhere hundreds of people met to honor the teenager described by her grandfather as wise beyond her years.To think such a bright light is extinguished at such a young age senselessly, Sparrow's grandfather, Tom Mason, said at one vigil last month. This was not an illness. This was not even a car accident. It was an act of violence. Its inconceivable.Although prosecutors do not state in court documents why Sharp wanted to kill his ex-girlfriend, they do reveal the 19-year-old admitted the crime was premeditated and that he and Stalczynski murdered Sparrow in the afternoon/evening hours the day the teenager went missing.On Tuesday, Jennings stressed his office cannot reveal any possible motives or additional details about the grisly crime because prosecutors are ethically restrained, for good reason.We want to make sure that fair trial rights are preserved, and quite frankly, we cannot imagine how painful this is for Madison's family and friends, Jennings said. We don't want them to suffer anymore.Read more at The Daily Beast.Got a tip? Send it to The Daily Beast hereGet our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.

Visit link:
Save $50 and take a deep dive into your pups genetics with this dog DNA test - Yahoo News

Direct-to-Consumer Genetic Testing: Global Markets and Technologies – GlobeNewswire

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" - https://www.reportlinker.com/p05987656/?utm_source=GNW

This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR) and genotyping microarrays.

The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2019 through September 2020. Industry subsectors analyzed include ancestry, clinical health, recreational health, sequencing data-based blockchain, sequencing instrument, long-read sequencing, sequencing informatics and PCR.

The market for DTC genetic testing is analyzed in depth. The market is analyzed by test purpose (ancestry, health, lifestyle); by technology platform (PCR, genotyping arrays, sequencing); by delivery format (test kits, virtual tests); and by geography (North America, Europe, Asia/Pacific, RoW).

The ancestry market segment is analyzed by technology and by ethnicity (African, Asian, European, Latino, other). The health market segment is analyzed by technology and by disease category (cancer, cardiovascular, complex common, pharmacogenomics, rare diseases and other). The lifestyle market segment is analyzed by technology and by application (genetic relatedness, nutrigenomics, personal traits, weight management/fitness, other)

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

More than 55 companies in the DTC genetic testing industry are profiled in this report.

The analyst provides a summary of the main industry acquisitions and strategic alliances from January 2019 through September 2020, including key alliance trends.

Report Inludes: - 12 data tables and 39 additional tables - An overview of the global markets and technologies for direct to consumer (DTC) genetic testing - Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025 - Information on key genomic regions associated with genetic testing and description of instruments and technologies used for DTC genetic testing - Coverage of DNA sequencing; microarray; and software industries and description of the key initiatives in the genetic testing industry - Detailed analysis of the current market trends, market forecast and discussion of technological, regulatory and competitive elements as well as economic trends affecting the future marketplace for direct to consumer (DTC) genetic testing and impact analysis of COVID-19 on the market - Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry - Profiles of the key companies in the DTC testing industry, including Chendu 23Mofang Biotechnology Co. Ltd (23Mofand), Genetic Technologies Ltd, Illumina Inc., Myriad Genetics Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc.

Summary: Direct-to-consumer (DTC) genetic testing involves the analysis and interpretation of a persons genome. A consumer can access DTC genetic testing from a commercial company or from a health care provider.

DTC genetic testing has evolved in the past 10 years. Initially it focused on personal applications outside traditional health care, such as exploring ancestry and has trended toward interfacing with clinical care in non-traditional ways, such as partnerships between DTC companies with health systems.

Analysis of a customers genome helps to know about their ancestry inference, disease risks and other personal traits. Based on this, the main applications include ancestry, health and lifestyle.

Several factors are driving growth in the DTC genetic testing industry, including a shifting emphasis on health-related applications, the rise of personalized genomics and increasing convenience of ordering goods and services from virtual at-home settings. This latter trend has been accelerated by the COVID- 19 pandemic.

There is rising public awareness of DNA and its impact on health and genetic disorders, ancestry and lifestyle. These trends are having a favorable impact on the at-home genetic testing market. This report provides an in-depth analysis of the DTC genetic testing industryRead the full report: https://www.reportlinker.com/p05987656/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

View original post here:
Direct-to-Consumer Genetic Testing: Global Markets and Technologies - GlobeNewswire

Genetics Tied to Thromboembolism Risk With Inflammatory Bowel Disease – HealthDay News

WEDNESDAY, Nov. 18, 2020 (HealthDay News) -- Genetic variants in some patients with inflammatory bowel disease (IBD) are associated with a significantly increased risk for developing thromboembolic disease (TED), according to a study published online Oct. 21 in Gastroenterology.

Takeo Naito, Ph.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues used whole-exome sequencing and genome-wide genotyping to determine the proportion of 792 IBD patients genetically at risk for TED and investigate the effect of the genetic risk for TED in IBD.

The researchers found that 122 of 792 IBD patients (15.4 percent) were genetically at high risk for TED. Among the 715 patients with documented TED status, 8.8 percent had TED events. There was a significant association between genetic TED risk and increased TED events (odds ratio, 2.5). The investigators also observed an additive effect of monogenic and polygenic risk on TED. There was more frequent thrombosis at multiple sites seen among patients with high TED genetic risk (78 versus 42 percent; odds ratio, 3.96).

"Our results suggest that genetic traits identify approximately one in seven IBD patients who will experience 2.5-fold or greater risk for TED," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Abstract/Full Text (subscription or payment may be required)

Here is the original post:
Genetics Tied to Thromboembolism Risk With Inflammatory Bowel Disease - HealthDay News

LANES, Fulgent Genetics and LA County Department of Health Services Collaborate to Fast-Track COVID-19 Test Results to Local Healthcare Providers -…

LOS ANGELES, Nov. 18, 2020 /PRNewswire/ -- Today, the Los Angeles Network for Enhanced Services (LANES) and TheLos AngelesCountyDepartmentof Health Services (DHS) announced their co-partnership with Fulgent Genetics Inc. (NASDAQ:FLGT) to support the data exchange of coronavirus tests performed at nearly 20 local drive-thru, walk-up and community clinic testing sites. As COVID-19 infections hit record levels in LA County, access to the most relevant test data is essential for healthcare providers to inform patient care decisions.

"We're committed to broad-scale Los Angeles County public health response to help our medical community participants significantly curtail the outbreak," said Ali Modaressi, CEO of LANES. "Our collaboration with Fulgent Genetics and DHS will fast-track getting COVID-19 test results in the hands of our dedicated Los Angeles providers who use our health information exchange platform. Physicians and other clinicians can view their patient's test results along with other pertinent clinical information in real time to make the best treatment decision for the patient."

Since May 25, Fulgent Genetics has administered thousands of laboratory-developed tests daily at community sites across Southern California to support the state's public health pandemic crisis. The partnership facilitates the electronic sharing of COVID-19 test results with DHS and LANES. LANES serves as the community's connectivity conduit posting COVID-19 test results to the patient's electronic health record (EHR) within 24 hours turnaround of the resident being tested.

According to James Xie, Chief Operating Officer, Fulgent Genetics, "Fulgent Genetics is committed to delivering up-to-the-minute COVID-19 test results through our COVID testing technology platform. The fast availability of our trustworthy results data shared through DHS and LANES is valuable for LA County officials and healthcare providers alike to aid in the public health detection, tracking, prevention, and management of the disease."

Many of the freestanding walk-thru and drive-thru testing sites are set up by DHS and other county public health agencies. In some cases, testing sites are unable to transfer the data to some community clinics lacking EHR connectivity capabilities.

LANES is the first HIE in the greater Los Angeles area to take action making COVID-19 testing results easily accessible to doctors, nurses and clinicians delivering care on the front lines. Additional value is offered in the platform's notifications at the population level that empower providers to be proactive when they see five out of 20 patients tested positive, for example.

"One of the faster online ways to disseminate test results to community providers, particularly for county clinics and hospital systems, is through an established health information exchange," said Clemens Hong, M.D., lead of COVID-19 testing at DHS.

"When a patient seeks care at a community hospital or clinic, it's really important for a provider to have that prior COVID-19 test result," continued Dr. Hong. "And since LANES assures proper patient identification matching, providers avoid duplicate testing while ensuring the most timely and informed care possible for the individual based on the results at hand."

For more information including locations about COVID-19 testing sites offered through the County of Los Angeles, visit https://covid19.lacounty.gov/testing/.

About LANES Los Angeles Network for Enhanced Services (LANES) is a community-based health information exchange (HIE) serving more than 500 health systems, hospitals and clinics that administer care to residents of Los Angeles County. Medi-Cal providers can tap Cal-HOP funds to access LANES. Connect with us onTwitterandLinkedInor visit theLANES websitefor more information.

About TheLos AngelesCountyDepartmentof Health Services (DHS) The Los Angeles County Department of Health Services (DHS) is the second largest municipal health system in the nation. Through its integrated system of 27 health centers and four hospitals - and expanded network of community partner clinics DHS annually provides direct care for 600,000 unique patients, employs over 23,000 staff, and has an annual budget of over $6.2 billion. For additional information regarding DHS please visitwww.dhs.lacounty.gov.

AboutFulgent Genetics, Inc. Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing ("NGS") with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs.

Media Contact: Angela Jenkins Angela Jenkins & Associates for LANES 303.877.0115 [emailprotected]

Media Contact: Los Angeles County Joint Information Center - COVID-19 424.241.3775 [emailprotected]

Media Contact: Jeff Fox The Blueshirt Group [emailprotected]

SOURCE Los Angeles Network for Enhanced Services

Home (New)

See the original post here:
LANES, Fulgent Genetics and LA County Department of Health Services Collaborate to Fast-Track COVID-19 Test Results to Local Healthcare Providers -...

Ancient Dog DNA Reveals Their Enduring Connection With People – WIRED

After that domestication event, some things do seem to have stayed constant. According to the teams results, after dogs split off from wolves over 11,000 years ago, wolves never made a major reentry into dog populations (until, perhaps, the contemporary craze for wolfdogs). Given that dogs and wolves belong to the same species and produce perfectly healthy offspring, this discovery came as a surprise to the authors. They inferred this result from the observation that some wolves are equally related to all ancient and modern dogs, which indicates that all dogs have the same amount of wolf ancestry. The logical explanation is that wolves didnt contribute substantially to the dog gene pool after domestication. If, instead, wolves had continued interbreeding with dogs, the team would have expected to observe that all wolves were more closely related to some dogswhich had wolves in their family trees post-domesticationthan others, which only had dog ancestors.

But, for some reason, the opposite happened when it comes to the wolf genome: Dogs are universally more related to some wolves than they are to others, which indicates that dogs did in fact contribute genetic material to wolf populations. This asymmetry between dogs and wolves may have a simple explanation: humans. It shows us, Lindblad-Toh says, that probably people held onto their dogs and took good care of them and made sure that they didn't let wolves in. The wolves had no such guardians.

But Liisa Loog, a postdoctoral researcher in the Genetics Department at the University of Cambridge who was not involved in the study, believes that it is important to keep this result in perspective. She notes that the authors argument depends on some specific assumptions about how ancient wolves relate to modern wolves, assumptions that are impossible to confirm without studying ancient wolves directly. The authors here rely on the assumption that this happened on a now-extinct wolf population that hasnt been sampled, and that is equally related to all modern-day wolf populations, she says. This may be the case, but it also may not be the case.

This assumption, and the assumptions about geographic and climatic consistency that undergird Bergstrm and Frantzs trade hypothesis, do mean that their results and theories cant be confirmed without additional research, like similar studies of ancient wolf DNA. But, ultimately, 27 dog genomes are a narrow window onto the past: When working with such a small amount of data, assumptions become necessary. The DNA itself is just DNA, Bergstrm says. It needs that wider context of interpretation.

The scarcity of evidence, coupled with the difficulty of extracting high-quality DNA from such old bones, might make ancient DNA research seem like a foolhardy endeavorwhy not just obtain genetic samples from modern dogs and figure out the family tree from there? But ancient DNA also has some distinct advantages over modern DNA, especially when it comes to dogs. Many contemporary dogs owe their genetic profiles to the Victorian dog breeding craze, so the signatures of their more distant past may be difficult to discern. Looking for evidence about ancient dogs in the genomes of modern ones is like searching for a needle in a haystack, Loog says. So it can help to go directly to the source. Ancient DNA, Loog says, literally gives us this time-stamped genetic picture of the past.

So, while it may be difficult to learn about prehistoric dogs by studying their modern descendants, the special insights afforded by ancient DNA can provide invaluable context for understanding how humans relate to dogs today. Dogs are kind of unique in that they are a predator, a carnivore. And they were domesticated by hunter-gatherers, way before agriculture, and they were also able to spread so quickly to most groups, Bergstrm says. Its somehow a surprisingly good fit for the human species to take on this animal as a companioneven though, a priori, it seems like an unlikely candidate for domestication. If Bergstrm and his colleagues are right, the human tradition of living with, breeding, and protecting dogs, and of treating canines not just as useful tools but as sources of social connection and emotional support, could have an 11,000-year history. Even before they figured out how to cultivate crops, humans may very well have known how to take care of, and be taken care of by, their animals.

More Great WIRED Stories

See the article here:
Ancient Dog DNA Reveals Their Enduring Connection With People - WIRED

Endometriosis and depression: is there a genetic link? – ABC News

Norman Swan: For something that affects one in three women and costs sufferers about $30,000 a year in lost work and healthcare costs, we don't know enough about endometriosis. That's when the tissue similar to the lining of the uterus grows elsewhere in the body and can cause pain, especially pain in the pelvis, and even infertility. And so awareness of endometriosis is much better than it used to be but it was often dismissed as a women's issue. But a new genetic study is showing endometriosis has a genetic link to depression and gut issues and there might be a cause-and-effect link. Hi Tegan, you've been looking at this.

Tegan Taylor: Hi, yes, it's a crazy link to be showing, isn't it. It's the sort of thing where you go maybe if you had debilitating pain every month and your doctors couldn't give you an answer, it wouldn't be surprising if you are depressed. But actually looks like the genetic cause and effect link actually works in the other direction.

Norman Swan: So tell me about the study.

Tegan Taylor: So this is a really big study that looked at a couple of big genetic databases, and basically they were looking for a shared genetic risk factor for depression and endometriosis because they knew that observational studies have shown that in women with depression, they are twice as likely as the general population to have endometriosis, and similarly in women with endometriosis they are twice as likely as the general population to have depression. So there seemed to be a link there.

And so they were looking for a shared genetic risk factor, and they found several actually. And then when they did more analysis, they showed this cause-and-effect relationship between depression on endometriosis, and they both seemed to have a causal relationship with something that is involving the gastric mucosa, so gastrointestinal reflux disease or gastritis peptic ulcers. And so there does seem to be some kind of linear relationship between the genes that are maybe malfunctioning to cause these gastric conditions and things like depression and endometriosis.

Norman Swan: These studies are called Genome Wide Association Studies, so they are not gene sequencing, they are looking at 700,000 separate points in the genome, and these points called SNPs are near where genes might be, and they have been criticised as exercises in just gathering data which might not be important or they might just be accidental associations.

Tegan Taylor: Yes, it fits into a broader field of research where we've got these observational studies on one side where it looks like people are more likely to have one of these things if they've got the other thing, but you can't show the cause-and-effect. And so I spoke to one of the researchers from the study, Dale Nyholt from the Queensland University of Technology, and he said that when you look at the genetics, you're able to draw a clean link between endo and these other conditions.

Dale Nyholt: As a geneticist, we always look at genetics because it's less influenced by some of these other environmental factors that could make something look like it's comorbid, but if we find shared genetic risk factors, well that's in your germline, so that's what you've inherited. And by doing these type of analyses that we've done, we really confirm and validate that there's something that's biologically shared across individuals that suffer these traits.

Norman Swan: That's Dale Nyholt from the Queensland University of Technology. So what does this mean for women living with endometriosis, Tegan?

Tegan Taylor: Well, when I started reporting on this study I thought I'd put the call out to my friends and family, see if there's anyone who I knew who had this experience. I was staggered by the number of people who replied, and the stories are just heartbreaking. And that idea of what Dale just said about validating, he was talking about validating in a scientific sense, but I think for women personally it is very validating to hear that this is a genetic thing.

Delayed diagnosis is really common with endometriosis. People don't feel seen or understood or, like you said at the beginning, they are dismissed as having women's troubles. But in addition to that, this lack of continuity of care and this frustration of being sent back and forth between doctors. So, one woman was being treated for endometriosis and was told that she had irritable bowel syndrome, but when she saw a gut doctor they were, like, no, you've got endometriosis, and she is just being flicked back and forth between specialists. So this appreciation that these cases might be interlinked is really valuable.

And so one of the people I spoke to was Sophie Volker, and she's got a history of depression as well as endometriosis and gut problems, but like many women it took her a really long time to get a diagnosis, and her doctors didn't immediately draw the link between the three conditions.

Sophie Volker: I had had really painful periods, had had gut problems forever, just thought that was a pretty normal part of my life. And so I think the confusion of not having any kind of answers, not having a diagnosis and having pain all the time probably did contribute a little bit to my being depressed.

Norman Swan: That's Sophie Volker. I mean, it's fine to say there's a genetic link, and the researchers think it is cause and effect, but if it is cause and effect, what's the biological mechanism?

Tegan Taylor: They think it has something to do with inflammation, so these genetic pathways, it's not like the only job that they have is to give someone endo or to give someone depression, they're gene sequences that have to do with cell death and repair, and they do all sorts of different things, but they think that inflammation is playing a role.

And so one of theI mean, yes, you sort of do this genetic analysis and then it's up to some other group of researchers to figure out what to do with, but there have been some other studies already into whether diet interventions, for example a low FODMAP diet can be helpful in people with endometriosis, and they've had promising results. So this helps put that into context and it would be good to see more research in that space.

And it also has implications for the sorts of medications that people are prescribed. So if you've got a gut problem, then taking a nonsteroidal anti-inflammatory for your endometriosis pain might not be appropriate because you've got gut problems. But also because we do know what genetic pathways might be involved now, then those pathways and genes could be potential targets for drugs, especially in those people who have both endometriosis and depression.

Norman Swan: And I suppose the other thing is that there is evidence from some interesting antidepressants, tricyclics, that they can have odd effects that have got nothing to do with actually their antidepressant effects, and it could be that you start to use antidepressants not for necessarily their effect on depression but they could have an effect on the endometriosis.

Tegan Taylor: Perhaps, exactly, and it also highlights the importance for screening. So if you've got someone coming in with, say, depression and gut problems and they are a woman, screening them for endometriosis as well because there is a higher than average likelihood that that woman also has endometriosis.

Norman Swan: Have we given GPs a lot of work after today's Health Report! You've got to work out the fish oil tablets, and you got to work out the depression and they've got problems in endometriosis, all serious issues.

See more here:
Endometriosis and depression: is there a genetic link? - ABC News

Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field – Newswise

Newswise BOSTON, Nov. 16, 2020 /PRNewswire/ --Apple Tree Partners (ATP), a leading life sciences venture firm, today announced the launch of Nereid Therapeutics, a company dedicated to discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates. ATP created Nereid with Clifford P. Brangwynne, Ph.D., professor in the Department of Chemical and Biological Engineering at Princeton University and an investigator at the Howard Hughes Medical Institute. Nereid commences operations with a $50 million Series A funding commitment from ATP.

Brangwynne, a biophysicist, is a pioneer of the field of biomolecular condensateswork for which he has won numerous awards, including a 2018 MacArthur Foundation "Genius" grant. He has discovered and elucidated the biophysical principles underlying how liquid-liquid phase separation drives the organization, material properties, function, and dysfunction of these ubiquitous structures in living cells. The Nereid drug discovery platform builds from a set of proprietary technologies, developed in the Brangwynne Lab at Princeton, that utilize advanced microscopy and computer vision to enable the precise measurement, interrogation, and control of phase separation in living mammalian cells. The platform holds promise to enable completely new approaches to discovering and developing therapeutics across a range of diseases; Nereid's near-term efforts will focus on certain cancers and neurodegenerative disorders in which pathological protein behaviors are governed or influenced by phase transitions.

"We are excited to partner with Cliff, an originator of and luminary in the fast-expanding field of condensate biophysics, to translate the vast potential of this science into new medical treatments to improve patients' lives," said Spiros Liras, Ph.D., a venture partner at ATP who will be Nereid's interim CEO. "Nereid possesses a unique suite of technologies with unmatched capabilities in phase separation, droplet visualization, and machine-learning-enabled quantitative mapping and measurementand together these tools comprise a system well-suited to rapidly identify and study novel therapeutic interventions."

The Nereid Board of Directors chaired by Seth Harrison, M.D., ATP's founder and managing partner, includes ATP venture partner and Chief Scientific Officer Michael Ehlers, M.D., Ph.D.; Liras; and Robert J. Hugin, former Chairman and Chief Executive Officer of Celgene Corporation. Brangwynne will maintain a Board observer seat and will chair Nereid's Scientific Advisory Board.

Clifford Brangwynne received a B.S. (2001) in Materials Science and Engineering from Carnegie Mellon University and a Ph.D. (2007) in Applied Physics from Harvard University. He was a postdoctoral researcher at the Max Planck Institute of Molecular Cell Biology and Genetics and the Max Planck Institute for the Physics of Complex Systems from 2007 to 2010, prior to joining the faculty of Princeton University in 2011, where he is currently a professor in the Department of Chemical and Biological Engineering, and an investigator at the Howard Hughes Medical Institute. His pioneering work on biomolecular condensates has been recognized with numerous awards, including a Macarthur Fellowship (2018), Wiley Prize (2020), Blavatnik Award (2020), and the HFSP Nakasone Award (2021).

About ATP

Founded in 1999, ATP is a leader in life sciences venture capital. ATP creates companies starting with assets at various stages, from working with scientists on pre-IP ideas, to spinning out assets from existing companies. We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises that create therapies for unmet medical needs.We invest in our companies from seed stage through IPO and beyond, enabling their success with our world-class team of venture partners and EIRs. For more information, visitwww.appletreepartners.com.

About Nereid Therapeutics

Nereid Therapeutics, an ATP company, is discovering new disease treatments using proprietary state-of-the-art technologies for generating, visualizing, and measuring liquid-liquid phase separation and the resulting biomolecular condensates. Nereid applies leading expertise in soft matter physics and cell biology to pioneer completely new ways to fight intractable diseases. For more information, visitwww.nereidtx.com.

Follow this link:
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field - Newswise

Frederick Health Hospital Physician Named One Of 10 Top Doctors In The Area – WFMD

November 16, 2020 - 2:05 pm

Its the third time for Dr. Meredith Wenick.

Frederick, Md (KM)) Washingtonian Magazines annual list of top doctors in the region includes a Frederick Health Hospital physician. Doctor Meredith Wernick was picked for the third time by the magazine as one of its top doctors in Maryland, Virginia and Washington DC. She was received this recognition in 2018 and 2019.

Being recognized by my colleagues in this way is truly an honor, Dr. Wernick says in a statement. Im very proud of the care we provide at Frederick Health. What I do is only possible thanks to our dedicated doctors, nurses and staff, al of whom have worked tirelessly to ensure uninterrupted treatment for our patients under extraordinary conditions since March.

Dr. Wernick is board-certified radiation oncologist who works with the Hospitals Radiation Oncology team.

She received her bachelors degrees in chemistry and molecular and cell biology at the University of California at Berkeley in 1996, and spent four yours as a researcher at the UCSF Center with a focus on the genetics of breast cancer, according to a news release from Frederick Health Hospital.

Dr. Wernick completed her medical training at Georgetown University, where she also completed an internship in internal medicine.

She currently sees patients at the James M. Stockman Cancer Institute in Frederick.

Dr. Wernick live in Potomac with husband and two sons.

By Kevin McManus

Go here to read the rest:
Frederick Health Hospital Physician Named One Of 10 Top Doctors In The Area - WFMD

Adaptive tuning of cell sensory diversity without changes in gene expression – Science Advances

INTRODUCTION

A central question in cell biology is how a population of cells deals with an ever-changing environment. A canonical paradigm for cellular responses to environmental challenges is the genetic switch, perhaps best exemplified by the lac operon (1), where cells sense changes in environmental factors and respond by changing gene expression. The response time scale of this strategy is limited by that of transcription and translation (~1 hour), leaving cells vulnerable to rapid fluctuations in the environment. A contrasting strategy that allows cells to cope with uncertain or rapidly changing environments is bet hedging, where cell populations diversify their phenotypes even within stable environments, by exploiting inherent stochasticity in cellular processes (26). Bet hedging allows subpopulations of cells to be prepared in advance, by maintaining a heterogeneous distribution of phenotypes matched to the repertoire of environments they might encounter in the future. Although genetic switching and bet hedging provide contrasting survival strategies with distinct advantages, they are not mechanistically exclusive. Bacteria can control the degree of phenotypic diversity in an environment-dependent manner by dynamically modulating gene expression noise (79). Here, we demonstrate that cells can modulate their phenotypic diversity even in the absence of gene expression changes through posttranslational processes, thus implementing fast control of phenotypic diversity.

The chemotaxis signaling pathway of Escherichia coli detects and responds to temporal changes in the extracellular concentrations of chemoeffector molecules through receptor-kinase complexes consisting of thousands of interacting two-state chemoreceptor proteins and kinases (6, 10). An adaptation mechanism, mediated by methylation and demethylation of the chemoreceptors, modulates the sensitivity of the system. Like in many other sensory systems in biology (1113), bacteria respond to relative changes in the signal (14), thus following the Weber-Fechners law of psychophysics (1517) and fold-change detection (FCD) (18, 19). The wealth of quantitative data that has been collected for this system through population-averaged measurements (14, 2023) provides a powerful foundation for examining how individual cells differ from the average in their sensory response and whether and how such diversity is modified upon adaptation.

To quantify the sensitivity of individual cells in the presence of different background-stimulus levels, we combined single-cell fluorescence resonance energy transfer (FRET) measurements of the chemotaxis signaling activity (24, 25) with a microfluidic system for fast stimulus modulation. We found that in the absence of any background signal, the individual cells sensitivities are distributed over about one decade of concentration, but upon adaptation to a background signal, the distribution of sensitivities narrows down to about one tenth of a decade, thus focusing the populations sensitivities to the relevant signal range. Combining experiments and mathematical analyses, we show how the population of cells exploits a standing variation in the degree of allosteric receptor coupling and the environment-dependent covalent modification of the receptors to tune the diversity in signaling sensitivities, which emerges in a class of allosteric models of two-state receptor activity. Crucially, this modulation of sensory diversity does not require any changes in the expression level of proteins, and hence, this mechanism can operate rapidly and in the absence of growth. Rather, it is a network-level property that arises through an adaptive change in the nonlinear mapping between molecular states and sensory phenotype.

To quantify the sensitivity of the chemotaxis system in individual E. coli cells, we stimulated them with short pulses of -methylaspartate (MeAsp)a nonmetabolizable analog of the chemoattractant aspartate (26)while monitoring the output of the signaling pathway using an in vivo single-cell FRET measurement of the activity of the kinase CheA (Fig. 1) (24, 25). To measure instantaneous responses of cells without confounding effects due to adaptation, we developed a polydimethylsiloxane (PDMS)based microfluidic device capable of fast (~0.1 s) switching between stimulus levels (see Materials and Methods, Fig. 1A, and fig. S1), nearly 100-fold faster than the cells adaptation time scale upon a small stimulus, which is on the order of 10 s (20). Cells grown to mid-exponential phase [optical density (OD) = 0.46 0.01] were washed in motility buffer and gently loaded in the device where they attached to the surface of the coverslip. We then subjected the cells to a sequence of eight identical subsaturating step stimuli presented over zero background while measuring the FRET level in each individual cell (~100 cells per experiment) (Fig. 1B). To avoid sampling highly correlated responses from a single cell due to the relatively slow temporal fluctuation in the kinase activity [correlation time ~12 s; (25)], measurements were conducted over >100 s with 15-s intervals between consecutive stimuli. A saturating step of MeAsp (>0.5 mM) was used to determine the FRET level corresponding to zero kinase activity at the beginning of each measurement (Fig. 1B). The FRET level after subtracting this zero-kinase level, hereafter called the FRET signal, is proportional to the kinase activity [see Materials and Methods; (21)].

(A) Fast and precise control of input stimuli within our bespoke microfluidic device. Top: Temporal profile of the ligand stimulus within the device, measured using a fluorescent dye. Our stimulus protocol involves one large stimulus followed by eight subsaturating step stimuli. Bottom: Superimposing multiple stimulus time series (each in a different color) demonstrates fast and highly reproducible relaxation for both steps up (left) and steps down (right). For a drawing and more details of the device, see fig. S1. (B) Responses are highly variable both across isogenic cells from the same growth culture and over time within the same cell. Response time series (FRET signal normalized by its steady-state level) for 5 representative cells out of the 133 measured in a single experiment are shown. Blue shading indicates times at which MeAsp step stimuli were applied (4 M, except the first stimulus, which was 0.5 mM). Gray circles indicate FRET response, and red lines indicate its moving average with a 1.5-s window. (C) Poststimulus activity is defined as the median FRET signal level (black line) during the 3-s step stimulus (blue shading) relative to the steady-state FRET level. (D) Summary of response variability upon 4 M MeAsp steps for all 133 cells measured in the experiment of (B). All responses (poststimulus activities) Ri (light gray) upon repeated application of identical steps are shown for every measured cell, sorted by rank of their median response R (dark gray). Note that Ri and R can take negative values due to measurement noise (fig. S2). The cumulative distribution of median response (traced out by the R point series) is broad, indicating extensive diversity across cells. a.u., arbitrary units.

The instantaneous response of a cell to a step stimulus was quantified by the poststimulus activity defined as the FRET signal relative to the steady state: Ri = Fi/Fss, where Fi is the median of the FRET signal over the 3 s during the ith step stimulus and Fss is the steady-state FRET signal, defined as the average over the entire time series except the time points during and right after the step stimuli (see Materials and Methods; Fig. 1C). The mean level of measurement noise for each individual response was 17% of the steady-state FRET signal (fig. S2), and the response distributions were stationary during the measurements (fig. S3). Sorting cells by their median poststimulus activity reveals substantial cell-to-cell variability (Fig. 1D), consistent with previous reports of phenotypic variability in this system (6, 25, 2730). Within each cell, we also observe large variations in the responses to identical stimuli (Fig. 1D, light gray dots), consistent with previous reports of temporal (behavioral) variability in individual cells adapted to a constant environment (6, 24, 25, 31). We ruled out cell cycle phase as a source of the cell-to-cell variation in kinase responses, as the latter demonstrated no correlation with cell length (fig. S4).

The standard method for determining the sensitivity of a signaling pathway is to fit the sigmoidal K1/2H/([L]H+K1/2H) to dose-response measurements and determine 1/K1/2 as the sensitivity of the cell. This approach has been used to quantify the dose response of populations of E. coli cells using FRET-based methods (21, 23, 32) and non-adapting single cells (25). However, this approach becomes impractical for measuring the response of single cells in the presence of adaptation because of the limited photon budget in single-cell FRET (25). Therefore, we devised an alternative strategy for determining the distribution of K1/2 within a cell population without the need to measure dose-response curves from individuals (Fig. 2).

(A) Principle of extracting the K1/2 distribution, p(K1/2), without dose-response measurements. K1/2, defined as the stimulus level that yields half-maximal poststimulus activity (R = 0.5), is typically determined by measuring dose-response curves (middle), which can vary from cell to cell. Here, we instead measure the distribution of R upon a stimulus of magnitude [L]j, p(R([L]j)), because the fraction of cells with K1/2 smaller than a given stimulus magnitude [L]j (p(K1/2 < [L]j); colored at the top) is equal to the fraction of cells whose poststimulus activity R([L]j) is less than one-half (p(R([L]j) < 0.5); colored at the bottom). (B) By repeating experiments of the type depicted in Fig. 1 at different stimulus step sizes [L]j, we build up the cumulative distribution of K1/2, p(K1/2 < [L]j). Each of the three panels on the left shows the summary of responses (as in Fig. 1D) for an experiment with a different [L]j (added MeAsp concentration, given in M by bold-faced numbers within panels), where sorting cells by their median poststimulus activity R (dark gray dots) provides the cumulative distribution of R, p(R([L]j) < r), corresponding to the fraction of cells whose response to [L]j is smaller than r (0 r 1). Using the identity illustrated in (A), the cumulative distribution of K1/2 (p(K1/2 < [L]j); rightmost) can be constructed by reading off values for p(R([L]j) < r) at r = 0.5 for each applied stimulus level [L]j. Error bars in the right show 95% bootstrap CIs.

To determine the distribution of K1/2, we exploited a simple identity relating the distribution of K1/2 to that of R, the (median) poststimulus activity of individual cells, which states that the fraction of cells with K1/2 smaller than a given stimulus magnitude [L] is equal to the fraction of cells whose (median) poststimulus activity R([L]) is less than one-half (Fig. 2A)p(K1/2<[L])=p(R([L])<0.5)(1)

Thus, from the distributions of the within-cell median poststimulus activities, one can construct the cumulative distribution function (CDF) of K1/2 of the population by determining, for each step stimulus intensity [L], the relative rank of the cell whose median poststimulus activity is 0.5 (Fig. 2B). Equation 1 is valid for any monotonic dependence of R on [L] and does not assume any specific steepness of a cells response curve or variation of it across cells.

Following this approach, we first determined the median of the poststimulus activity of individual cells adapted to a uniform environment with no MeAsp in the background, by stimulating cells with step stimuli that ranged from 0 to 30 M MeAsp (Fig. 3A). From these data, we extracted the distribution of K1/2 (inverse sensitivity), which was well approximated by a log-normal distribution (see Materials and Methods; Fig. 3, B and C). We found that in zero background, the sensitivity of individual cells to MeAsp was distributed over a wide range covering about one decade (~1 M < K1/2 < ~10 M).

(A) Summary of responses to step stimulation by MeAsp (gray dots: response to individual steps Ri, colored dots: median response of each cell R). Background concentration ([L]0) and step size ([L]) are shown in M at the top and within each panel, respectively. Cells are sorted by their median response. (B) Cumulative distribution of K1/2, p(K1/2 < [L]), of responses to MeAsp in cells adapted to three different background concentrations of MeAsp, [L]0 = {0,100,200} M, constructed from the data in (A) through the procedure outlined in Fig. 2. Curves represent fits by log-normal distributions. Error bars are 95% bootstrap CIs. The concentrations of stimuli used to define saturating responses are indicated by the triangles. (C) The distributions of K1/2 computed from the fits in (B) reveal that diversity in K1/2 is strongly attenuated upon adaptation to both 100 and 200 M MeAsp. Note that in this panel, the distribution at each background concentration is centered by normalizing K1/2 by the mode of the distribution to facilitate visual comparison. (D) Cumulative distribution of K1/2, p(K1/2 < [L]), of responses to serine in cells adapted to different background concentrations of serine, [L]0 = {0,1} M.

Given the well-characterized adaptation to ambient chemoattractant concentration at the population level, we wondered whether and how the single-cell distribution of sensitivities could be affected by adaptation to a constant nonzero background of MeAsp. Consistent with the population-level FRET measurements (14, 21), the average of the K1/2 distribution shifted with the background stimulus level due to sensory adaptation when cells were adapted to 100 M MeAsp before step stimulation (Fig. 3B). Unexpectedly, the diversity in response sensitivity across cells also changed drastically, with the K1/2 distribution becoming much narrower upon adaptation (Fig. 3C). A similar collapse in the K1/2 distribution width was found to occur for cells adapted to a higher (200 M) background of MeAsp. We further determined that this sensory diversity tuning is not specific to the MeAsp receptor Tar, as the distribution for serine, the cognate ligand of the other major chemoreceptor Tsr, demonstrated a similar collapse in width upon adaptation (Fig. 3D and fig. S5). Thus, the environment-dependent tuning of response diversity is not specific to a single receptor species and appears to be a general property of the bacterial chemotaxis network.

Recent studies have shown that cell populations can control the level of phenotypic diversity in an environment-dependent manner by modulating the variance of the protein abundance distributions (79). Here, by contrast, experiments were carried out under conditions in which neither the cognate receptors nor any other protein can be synthesized (due to auxotrophic limitation; see Materials and Methods). The observed tuning of sensory diversity must therefore be attributable to a mechanism that involves posttranslational processes rather than changes in gene expression.

To understand the molecular mechanism underlying this adaptive tuning of diversity in cell response sensitivities (Fig. 3), we turned to modeling. The receptor-kinase complexes of the chemotaxis system in E. coli and other species are arranged in hexagonal arrays of trimers of dimers that respond cooperatively to signals (33, 34). The activity of such clusters can be modeled using an extension of the Monod-Wyman-Changeux (MWC) model of allostery (35) and has been shown to agree with a large body of experimental data (20, 23, 3642). In this model (Fig. 4A and Supplementary Text), allosteric interactions between n coupled receptors form signaling teams within which all n receptors (and associated kinase molecules) share the same activity states (active or inactive). The free energy difference between the two receptor states is determined not only by the ligand concentration [L] (analogous to the oxygen concentration in the classical MWC model for hemoglobin) but also by the average methylation level m of receptors. Because of feedback from downstream adaptation enzymes, the value of m at steady state, in turn, depends on the background stimulus level [L]0, i.e., m = m([L]0). Kinase activity upon a step change in input from a given background [L]0 to another stimulus level [L] depends on two parameters n and m*, where m* is the receptor methylation level in the absence of ligand stimulus. Values of the parameters n and m* for E. coli chemoreceptors have been constrained by a large body of population FRET data (20, 21, 36, 37, 39, 42) and have been shown to vary as a function of expression level ratios between key chemotaxis signaling proteins (23, 25). Given that these ratios are affected by stochastic gene expression, the values of n and m* can vary across individual cells of the population (25), whereas values of other biochemical parameters (e.g., the dissociation constants of the receptors) are intrinsic to the structure of relevant proteins, which can be assumed invariant across isogenic populations of cells (see Supplementary Text).

(A) Schematic for allosteric MWC model of the receptor kinase complex. The effective number of coupled receptor dimers n affects the response of kinase activity a upon a step change in ligand concentration from [L]0 to [L], through the expression a = (1 + exp (f(n, m*, [L]0, [L])))1, where m* is the methylation level of the receptors in the absence of ligand. Both n and m* can vary across cells due to differences in gene expression. (B) Two limiting cases of cell-to-cell variation in the model parameters. Model 1 (red solid lines): m* is fixed, but n varies across cells. Model 2 (blue dotted lines): n is fixed, but m* varies across cells. (C to E) Fits of models 1 and 2 to the distribution of steady-state kinase activity a0 (C), population-averaged dose-response curves (D), and distribution of logK1/2 (E). Black corresponds [in (C) and (D)] to measured data and [in (E)] to probability density computed from model fits to cumulative distributions (see fig. S7). Error bars represent 95% bootstrap CIs.

The observed diversity in K1/2 values might thus reflect cell-to-cell differences in the value of n, m*, or both. To discriminate between these possibilities, we first considered two models that represent limiting cases (Fig. 4B and fig. S6). In model 1, the value of m* is fixed across cells, but the value of n varies across the population. In model 2, n is fixed and m* varies. Both models could fit the distribution of steady-state kinase activity (Fig. 4C) previously measured in isogenic populations (25), as well as the population-averaged dose-response data (Fig. 4D). However, the two models yield contrasting predictions for the underlying diversity in single-cell sensitivity. Whereas model 1 with variability only in the size of receptor coupling n demonstrated a tuning of K1/2 diversity upon adaptation to MeAsp in close agreement with the experimental data, model 2 with variability only in m* demonstrated little or no diversity tuning, with the width of the K1/2 distribution remaining approximately constant, with or without adaptation to MeAsp (Fig. 4E). A more general model in which both n and m* vary across cells also yielded consistent results: Fitting with this model yielded a broad distribution for n (CV(n) = 0.41) but a very narrow one for m* (CV(m*) = 0.02) (fig. S8). In a similar manner, the observed diversity tuning of response sensitivity to serine stimuli could also be explained by the variation in the number of coupled Tsr receptors while keeping m* fixed (fig. S5).

Thus, MWC modeling implicates as the predominant source of response diversity a single parameter, the degree of allosteric coupling n for the receptor cognate to the applied ligand stimulus. The model yields excellent fits to the changes in the shape of the K1/2 distribution p(K1/2) upon adaptation without assuming any changes in the underlying parameter distribution p(n). Consistently, further model-based analysis of the dose-response data (fig. S9 and Supplementary Text) did not detect significant changes in the distribution p(n) over the different backgrounds [L]0 across which diversity tuning (i.e., a change in the width of p(K1/2)) is observed. These modeling results thus suggest that while variation in n is the key ingredient for response diversity, the posttranslational mechanism that accounts for adaptive tuning of that diversity does not require a change in the degree of variation in n across cells.

To pinpoint the mechanism responsible for diversity tuning with the MWC model, we focused on the simplest variant (model 1) that reproduced the observed diversity tuning assuming cell-to-cell variation in only a single parameter, n. We first investigated how diversity in K1/2 (as quantified by its coefficient of variation, CV(K1/2)) depends on the adapted state background [L]0 in this model while holding fixed the distribution p(n). CV(K1/2) demonstrated two plateaus: At low [L]0, K1/2 is highly variable with CV(K1/2) approaching 0.5, whereas at high [L]0, diversity is strongly suppressed with CV(K1/2) attenuated by nearly an order of magnitude (Fig. 5A, gray curve). Thus, diversity in response sensitivity demonstrates two regimes: high diversity at low [L]0 and low diversity at high [L]0.

(A) The adaptive MWC model predicts a switch from high to low sensory diversity as the background stimulus level [L]0 is increased from zero. The coefficient of variation of K1/2 (CV(K1/2)) at [L]0 = 0 M and [L]0 = {100,200} M MeAsp (black points) falls within the high- and low-diversity regimes, respectively, predicted by model 1 (gray curve). To test the predicted transition regime, we measured the K1/2 distribution at the crossover point [L]0*=KI(e(m0m*)1)2.1M (dotted line). The measured CV (magenta) for cells adapted to [L]0=2M([L]0*) is in excellent agreement with the model prediction (blue point). All CV values were computed from parameters of the log-normal distributions fitted to the CDF of K1/2 (fig. S12). Error bars were computed by propagating the SE of the parameters. (B) The model accurately predicts the full distribution of K1/2 diversity and the population-level response at [L]0*. Model prediction (blue) and experimental results (magenta) for the population dose-response curve (top), CDF (middle), and probability density function (PDF, bottom) of K1/2 at [L]0 = 2 M MeAsp. Model parameters were constrained only by the data at [L]0 = {0,100,200} M data (Fig. 4), with no additional fit parameters for the [L]0 = 2 M data. Model behavior at [L]0 = {0,100,200} M backgrounds is shown for reference (gray dashed curves). Error bars represent 95% bootstrap CIs.

A key quantity that determines how the diversity in n affects diversity in K1/2 is the susceptibility of K1/2 with respect to n, defined by the absolute partial derivative n log (K1/2). In broad terms, when this susceptibility is high, variation in n contributes strongly to diversity in K1/2; when it is low, the effects of variation in n can be suppressed. We found that the susceptibility n log (K1/2) computed using the MWC model (and evaluated at the population mean, n = n) also exhibits a decreasing profile as a function of [L]0 with two plateaus (fig. S10), closely mirroring the CV(K1/2) profile (Fig. 5A, gray curve).

The existence of two regimes with contrasting susceptibilities n log (K1/2) has been predicted theoretically for chemoreceptor MWC models [fig. S11; (37)]. In this class of models, the methylation-dependent free energy difference between the active and inactive states of ligand-unbound receptors follows a linear relationship fm = (m([L]0) m0), where corresponds to the free energy per methyl group, and m0 is an offset methylation level at which fm = 0. Because of nonlinearities arising in the allosteric mechanism, the dependence of K1/2 on n changes qualitatively as the methylation level crosses m0 [fig. S11; (37)]. When the methylation level is low (i.e., m([L]0) < m0), K1/2 becomes inversely proportional to n (specifically, K1/2 KI/n, where the dissociation constant of the inactive receptor KI sets the concentration scale), and therefore, the degree of receptor coupling n strongly affects sensitivity. In this regime, the susceptibility n log (K1/2) is thus high, and we can expect cell-to-cell variation in n to cause substantial K1/2 diversity across cells. Conversely, when the methylation level is high (i.e., m([L]0) > m0), K1/2 becomes independent of n (37). In this regime, the susceptibility n log (K1/2) is thus low, and we can expect K1/2 diversity to be suppressed. The crossover between the two regimes is set by the offset methylation level m0 at which the free-energy contribution from covalent modification feedback vanishes (i.e., fm = (m([L]0) m0) = 0). Thus, the drastic difference in diversity we found at zero and high (100 and 200 M) background concentrations (Fig. 5A, black points) could be explained by the switch from high to low susceptibility n log (K1/2) as the adapted-state covalent modification level m([L]0) increases beyond m0.

The success of the adaptive MWC model in explaining the observed response diversity motivated us to further test its predictive power: Given the model calibrated by data obtained so far in the high- and low-diversity regimes, how accurately could we predict K1/2 diversity at an as-yet unmeasured background concentration? Using experimentally determined values for the parameters KI, , m0 (14, 20), and m*, the crossover background concentration [L]0* at which the adapted state modification level reaches m0 (i.e., m([L]0*)=m0) is readily computed from the model (see the Supplementary Materials) as [L]0*=KI(e(m0m*)1)2.1 M MeAsp (Fig. 5A, vertical dashed line), at which the model predicts an intermediate level of K1/2 diversity (Fig. 5A, blue point). We thus opted to measure the distribution of K1/2 at a background of 2 M (Fig. 5 and fig. S12). The results are in excellent quantitative agreement with model predictions not only at the level of CV(K1/2) (Fig. 5A, magenta point) but also for the entire shape of the distribution (Fig. 5B, middle and bottom) and population-level response (Fig. 5B, top).

Thus, the adaptive MWC model of chemoreceptors provides not only a mechanistic explanation for but also predictive power over the observed diversity tuning in the bacterial chemotaxis system, in which posttranslational receptor modification mediates the transition between two regimes of sensory diversity: When the background stimulus level is low (regime I), receptor modification falls below m0 and diversity is augmented; when the background stimulus is high (regime II), modification exceeds m0 and response diversity is attenuated.

By combining a novel microfluidic device with a single-cell FRET assay, we characterized the diversity of chemoeffector responses and its dependence on background stimulus conditions within isogenic populations of E. coli. We found that the width of the sensitivity distribution is strongly modulated in an environment-dependent manner under experimental conditions (auxotrophic limitation) that do not permit gene expression changes. Mathematical modeling provided remarkably accurate predictions and a mechanistic explanation for this diversity tuning that requires only a change in the posttranslational modification of signaling proteins. Below, we discuss the molecular requirements and functional implications of this novel mechanism for diversity tuning, as well as the significance of its implementation without changes in gene expression.

It has long been known that the intracellular variable modulating bacterial chemotactic sensitivity upon sensory adaptation is the covalent modification level m of chemoreceptors (43, 44). Naively, therefore, one might expect the diversity in sensitivity we observed across cells to be the result of cell-to-cell differences in this key internal variable. Our MWC model analysis revealed, however, that the main contribution to response diversity comes not from m but instead from n, the degree of chemoreceptor coupling. While n is a coarse-grained parameter that can be affected by both the size and composition of receptor clusters, the likely dominant contribution to its variation is the expression-level ratio between the two major receptor species Tar and Tsr, which has been shown to vary strongly across cells (45). A recent study in adaptation-deficient cells found that the diversity in dose-response parameters (K1/2 and the Hill coefficient, H) across cells could be largely explained by variation in this ratio (25). Varying the Tar/Tsr ratio determines the direction of chemotactic cell migrations when subjected to two conflicting chemoeffector gradients (46)whereas cells with high Tar/Tsr ratios migrate preferentially toward MeAsp (the cognate ligand for Tar), cells with low Tar/Tsr ratios do so toward serine (the cognate ligand for Tsr). Thus, the diversity in response sensitivity we observed in our FRET experiments can be interpreted to reflect diversity in sensory preference, which could, in turn, significantly affect population-level chemotactic performance in environments that present multiple stimuli.

Optimal strategies for biological adaptation depend on accessible information about the environment (47, 48). When environmental cues provide sufficiently accurate information, tracking strategies that accordingly adjust phenotypes can provide an advantage. When environmental cues do not carry sufficient information, bet-hedging strategies can provide readiness of different individuals to different environments.

For sensory adaptation in bacterial chemotaxis, the zero-background condition is singular in that there is no information about the nature of future environmental signals. E. coli cells express five types of chemoreceptors (Tar, Tsr, Tap, Trg, and Aer) that sense a variety of stimuli (10). Given that the relative expression levels of these receptors are highly variable across cells (45) and that different receptor species are mixed within clusters (49), the combinations of the effective degree of coupling for each receptor type realized in a cell population are numerous.

The switch-like transition in K1/2 diversity we observed (Fig. 5) enables cells to diversify their response sensitivities (and hence sensory preference) for different ligands when all ligand concentrations are near zero and uncertainty is at a maximum (Fig. 6A). This could be beneficial in improving the readiness of the isogenic population for many future signalsa sensory bet-hedging strategy. By contrast, once a relevant signal is detected, such as a gradient of aspartate, cell-to-cell variability in sensitivity can lead to detrimental desensitization (when sensitivity is too low) or sensory saturation (when sensitivity is too high) that precludes effective tracking of the signal as cells climb the gradient by chemotaxis. Our experiments revealed that the width of the distribution of sensitivities is markedly reduced upon adaptation to higher ligand concentrations, therefore focusing the population on tracking that signal. In summary, this novel mechanism of sensory diversity tuning could enable an isogenic population to be ready for any signal when the environment is uncertain but switch to tracking a specific signal once it is detected.

(A) Diversity tuning in chemotactic response sensitivity. In environments with low background signals below the crossover level ([L](x)<[L]0*), uncertainty about future signals is high, and the population diversifies its sensory preference. In environments with high background signals above the crossover level ([L](x)>[L]0*), the population can attenuate its sensory diversity and switch to tracking the perceived signal. (B) Phenotypic diversity can be tuned by environmental modulation of either gene expression or posttranslational processes. Top: Gene expressiondependent diversity tuning involves modulation of stochastic gene expression in response to environment changes (79), leading to different distributions of expressed protein counts across cells in different environments. This mechanism can tune phenotypic diversity without environmental modulation of posttranslational expression-phenotype mappings (represented here by the box labeled by f). Bottom: By contrast, the posttranslational diversity tuning mechanism we found in this study involves environmental modulation of the expression-phenotype mapping (f, implemented in bacterial chemotaxis by covalent modification of allosteric chemoreceptors). This mechanism requires no environmental modulation of gene expression and hence can achieve rapid tuning of phenotypic diversity.

Another challenge unique to the zero-background signal condition is that there is no information about the magnitude of the future signal. In dealing with the uncertainty in the signal strength, two key performance measures of a cell population as a sensory system are the width of the range of input signals over which it can respond (response range; fig. S13A) and the degree to which the input signal is amplified at the output level (gain; fig. S13A). For a homogeneous cell population with a sigmoidal stimulus-response curve, it is known that there is an inherent trade-off between these two performance measures (50, 51). A large response range requires a shallow response curve, but this inevitably reduces the response gain, and vice versa (fig. S13B). To understand whether and how the diversified sensitivity contributes to the performance of a cell population, we computed the performance measures of gain and response range in the zero-stimulus background condition using the MWC model and compared a cell population with diversity in the number of coupled receptors n to a hypothetical homogenous population (fig. S13B). As expected from the diversity in the sensitivity due to the variation in n, the diverse population exhibits a broader response range than the homogeneous population (fig. S13B). On the other hand, each individual cell in the diverse population maintains a high response gain (fig. S13B), reflecting the insensitivity of the gain to the variation in n in the low-background signal regime of the coupled two-state receptors (37). Thus, a population with diverse sensitivity can outperform homogeneous populations in dealing with the unpredictability associated with the zero background.

As noted above, the high- and low-diversity regimes we found here were identified in an earlier theoretical study as regimes I and II, respectively, of cooperative chemosensing (37). In that study, it was found that cooperativity (i.e., n > 1) extends the dynamic range of sensing to lower concentrations due to the 1/n scaling of K1/2 in regime I, whereas it increases signal gain by increasing the steepness of response (i.e., the Hill coefficient, H > 1) in regime II. Subsequent studies found that when E. coli cells are adapted to higher concentrations in regime II ([L]0 KI), responses to step changes (39) and time-varying signals (18, 19) depend only on relative changes of chemoeffector concentrations (14). This property of FCD provides a robust sensory strategy in many natural contexts where absolute signal intensities tend to carry less information than relative contrast (19). By contrast, in regime I of cooperative sensing ([L]0<[L]0*), the sensory response becomes proportional to the absolute change in chemoeffector input. Although this connection between the cooperative sensing regimes and FCD is intriguing, we note that the diversity tuning we found here is not causally related to FCD. One can construct a network model that demonstrates the linear-response/FCD transition but does not demonstrate diversity tuning (see the Supplementary Materials and fig. S14). Evidently, cooperativity in E. coli chemoreceptors provides multiple benefits in sensory performance: increased dynamic range/signal gain, FCD, and diversity tuning of response sensitivity. The molecular parameters that define cooperativity and the resulting signaling regimes are thus likely under pleiotropic selection (52) and would provide fertile ground for future studies of trade-offs and optimality (53) in the design of allosteric signaling systems.

Recent pioneering studies have provided a handful of examples of how bacteria can modulate phenotypic diversity in an environment-dependent manner, by changing the distribution of protein abundance across cells [Fig. 6B, top; (79)]. By contrast, the diversity-tuning mechanism we found here is implemented by posttranslational processes (Fig. 6B, bottom). The mechanism hinges on a nonlinear relationship (represented by the box with label f in Fig. 6B, bottom) between the phenotype of interest (here, the response sensitivity or its inverse, K1/2), a gene expressiondependent parameter (here, the degree of receptor coupling, n), and a posttranslational variable that varies in response to the environment (here, the covalent modification state of chemoreceptors, m).

An important difference between gene expressiondependent and posttranslational mechanisms of diversity tuning lies in the achievable speed for environment-dependent modulation of diversity. Whereas the former is limited by the time scale of gene expression (typically measured in minutes), the latter can be implemented by much faster biochemical processes (the fastest covalent modifications occur on subsecond time scales). Another significant difference is in biochemical costs and requirements: Gene expressiondependent diversity tuning requires synthesis of new proteins and hence may be rendered useless under nutrient-limited conditions, whereas the posttranslational mechanism studied here could be operational in any environment that supports the required type of covalent modification (here, methylation). Thus, posttranslational diversity tuning could be advantageous when cell populations need to adapt to fast-switching environments such as the gut (54, 55) and/or under poor nutrient conditions such as marine environments (56). Given the ubiquity of nonlinear functions throughout cellular biochemistry, we expect that posttranslational diversity tuning could play a role in the survival of a broad range of cell types in a variety of biological contexts.

The strain used is a derivative of E. coli K-12 strain RP437 (HCB33). The FRET acceptor-donor pair (CheY-mRFP and CheZ-mYFP) is expressed in tandem from plasmid pSJAB106 (25) under an isopropyl--d-thiogalactopyranoside (IPTG)inducible promoter with induction level of 50 M IPTG. The glass-adhesive mutant of FliC (FliC*) was expressed from a sodium salicylate (NaSal)inducible pZR1 plasmid (25) with induction level of 3 M NaSal. We transformed the plasmids in VS115, a cheY cheZ fliC mutant of RP437 [a gift of V. Sourjik; (25)], referred to as wild-type strain in the main text.

Microfluidic devices were constructed from PDMS on a 24 mm 60 mm cover glass (#1.5) following standard soft lithography protocols (57). Briefly, the master molds for the device were created with a positive photoresist (AZ 9260, MicroChemicals) on a silicon wafer using a standard photolithography technique (57). Approximately 20-m-high master molds were created. To fabricate the device, the master molds were coated with a 5-mm-thick layer of degassed 10:1 PDMS-to-curing agent ratio (Sylgard 184, Dow Corning). The PDMS layer was cured at 80C for 1 hour and then cut and separated from the wafer, and holes were punched for the inlets and outlet. The PDMS device was then bonded to a cover glass. The PDMS was cleaned with transparent adhesive tape (Magic Tape, Scotch) followed by rinsing with (in order) isopropanol, methanol, and Millipore-filtered water. The glass was rinsed with acetone, isopropanol, methanol, and Millipore-filtered water. The PDMS device was tape-cleaned an additional time before the surfaces of the device and coverslip were treated with a plasma generated by a corona treater. Then, the PDMS device was laminated to the coverslip and then baked at 80C overnight.

Sample preparation in the microfluidic device was conducted as follows: Of the five inlets of the device (fig. S1A), four inlets are connected to reservoirs (liquid chromatography columns, C3669; Sigma-Aldrich) filled with motility media containing various concentrations of MeAsp through polyethylene tubing (Fine Bore Polythene Tubing, 0.58 mm inside diameter, 0.96 mm outer diameter, Smiths Medical). Another inlet (located at the extremity) is connected to a reservoir filled with motility media containing fluorescein, which enables us to observe the flow of the solution and allows us to calibrate the pressure applied to the reservoirs before each experiment. The tubing was connected to the PDMS device through stainless steel pins that were directly plugged into the inlets or outlet of the device. Cells washed and suspended in motility media were loaded in the device from the outlet of the device and attached to the glass surface in the microfluidic device by reducing the flow speed inside the chamber. The pressure inside the reservoirs connected to the inlets was controlled by computer-controlled solenoid valves (MH1, Festo) that promptly switches between atmospheric pressure and higher pressure introduced from a source of pressurized air. The pressure applied to the reservoirs was adjusted before each experiment by observing the flow of the fluorescent solution under the microscope so that all stimulus solutions are delivered to imaging areas. The FRET measurements were conducted at three different positions in a microfluidic device, and an identical stimulus protocol was repeated at every position.

Single-cell FRET microscopy and cell culture were carried out essentially as described previously (25). In brief, cells from a saturated overnight culture were grown to OD 0.45 to 0.47 in 10 ml of tryptone broth (1% bacto-tryptone and 0.5% NaCl) in the presence of ampicillin (100 g/ml), chloramphenicol (34 g/ml), 50 M IPTG, and 3 M NaSal. Cells were collected by centrifugation (5 min at 5000 rpm) and washed twice with motility media [10 mM KPO4, 0.1 mM EDTA, 1 M methionine, and 10 mM lactic acid (pH 7)] and then resuspended in 2 ml of motility media.

FRET imaging in the microfluidic device was performed using an inverted microscope (Eclipse Ti-E, Nikon) equipped with an oil immersion objective lens (CFI Apo TIRF 60 Oil, Nikon). Yellow fluorescent protein (YFP) was illuminated with a light-emitting diode illumination system (pE-4000, CoolLED, for experiments with MeAsp stimuli, and SOLA SE, Lumencor, for experiments with serine stimuli) through an excitation bandpass filter (FF01-500/24-25, Semrock) and a dichroic mirror (F01-542/27-25F, Semrock), and the fluorescence emission was led into an emission image splitter (OptoSplit II, Cairn) and further split into donor and acceptor channels with a second dichroic mirror (FF580-FDi01-25x36, Semrock) and collected through emission bandpass filters (FF520-Di02-25x36 and FF593-Di03-25x36, Semrock) with a sCMOS (scientific CMOS) camera (ORCA-Flash4.0 V2, Hamamatsu). Red fluorescent protein (RFP) was illuminated in the same way as YFP except that an excitation bandpass filter (FF01-562/40-25 for experiments with MeAsp stimuli and FF01-575/05-25 for experiments with serine; both from Semrock) and a dichroic mirror (FF593-Di03-25x36, Semrock) were used. Additional excitation filter (59026x, Chroma) was used for experiments with serine stimuli. Before each time-lapse measurement, an acceptor image (RFP excitation and RFP emission) and a donor image (YFP excitation and YFP emission) were taken to estimate the RFP expression level and cell volume of each cell used for data analysis. In time-lapse imaging, images were acquired every 0.3 to 0.5 s.

The FRET level of each cell was calculated essentially in the same way as described previously (21, 25, 32). After flat-field correction of the fluorescent images, fluorescent signals, i.e., donor signal (obtained from donor channel: YFP excitation and YFP emission) and FRET-acceptor signal (obtained from FRET-acceptor channel: YFP excitation and RFP emission), were extracted from the images for each individual cell using an image segmentation technique. The extracted raw fluorescent time series were corrected for bleaching by fitting both donor and FRET-acceptor signals with a biexponential function and dividing out the decay to yield donor signal D(t) and FRET-acceptor signal A(t).

We define the FRET index as the decrease in the donor signal D(t), D (0), due to FRET between the donor (mYFP) and acceptor (mRFP1) molecule, normalized by the intensity of donor illumination reaching a cell through the donor excitation filter, D, and cell volume, VcellFRET(t)D/(DVcell)where D was extracted from the flat-field image, and Vcell was estimated from the no-binning YFP image. The FRET index was chosen because D/(DVcell) is proportional to the concentration of active CheA. To show this, we consider the following. First, D can be decomposed asD=DDEFRETQDLDSDtDDVcell[DA]where D, EFRET, QD, LD, SD, tDD, and [DA] are respectively the absorption coefficient of donor, the FRET efficiency of the complex, the quantum yield of donor, the throughput of the donor emission light-path, the quantum sensitivity of the camera for donor emission, the exposure time for the donor image, and the concentration of the donor-acceptor complex. Because D, EFRET, QD, LD, SD, and tDD are all constants once the experimental system is fixed, by introducing C = DEFRETQDLDSDtDD, we write D asD=CDVcell[DA]

So, the FRET index FRET(t) is proportional to [DA] or the concentration of CheYp-CheZ complex [CheYp CheZ]. The concentration of the complex reaches a quasisteady state on the time scale larger than the time scale of hydrolysis of phosphorylated CheY, CheYp, catalyzed by CheZ [~0.5 s; (22)] due to the balance between phosphorylation and dephosphorylation of CheY. Thus, the following holds[DA]=[CheYpCheZ]=akAkZ[CheA]=akAkZ[CheA]Twhere kA and kZ are respectively the rate constants for autophosphorylation of CheA and that for hydrolysis of CheYp by CheZ, a (0 < a < 1) is the fraction of active CheA, and [CheA]T is the total concentration of CheA (25). Given the conservation equation [CheA]T = [CheA] + [CheAp], the last step of the above equations holds when [CheAp] [CheA]T. This is achieved when sufficient amount of CheY-RFP and CheZ-YFP is present in the cell as verified previously (25), and therefore, we exclude cells from analysis whose concentrations of CheY-mRFP1 and CheZ-mYFP are low.

Together, the FRET index isFRET(t)=DDVcell=C[DA]=CkAkAa[CheA]T=Ca[CheA]Twhere C = CkA/kZ, which is invariant between cells. To increase the signal-to-noise ratio, D can be computed, rather than directly extracting from D(t), asD(t)=D0r(t)+r0+r(t)where r(t) A(t)/D(t) = r0 + r(t); r0 and D0 are the ratio r and donor signal D, respectively, in the absence of FRET, which is obtained by applying saturating stimulus to cells (21); and = A/D is the absolute value of the ratio of changes in the fluorescent signals due to FRET, which is a constant dependent on a measurement system (21, 25, 32). Fss was defined as the average FRET index excluding time points during and right after stimuli (15 s for a saturating stimuli and 6 s for subsaturating step stimuli). Fi was defined as the median FRET index during a step stimulus (10 time points). Response to each step stimulus Ri was defined as Ri = Fi/Fss.

A measured FRET time series FRET(t) can be conceptually decomposed into the true signal FRETtrue(t), which is proportional to the concentration of active CheA, and the measurement noise arising from the finite number of photons (t)FRET(t)=FRETtrue(t)+(t)

Because the true signal is also fluctuating, it is not trivial to estimate the magnitude of the measurement noise in general. However, we can exploit the fact that, when a saturating stimulus is presented, the true signal, and therefore also its variance, goes to zero (21) and henceFRET(tsat)=(t)

Thus, the variance of the FRET time series during a saturating stimulus can be equated with the measurement noiseVar(FRET(tsat))=Var()

When evaluating a FRET level upon a stimulus, we used the median value of n (=10) consecutive measurement points to mitigate the contribution of measurement noise. Because the measurement noise is delta correlated, the contribution of measurement noise is Var(FRET(tsat))/n. We estimated this quantity by computing the SE of the mean from n consecutive data points during saturating stimuli from each cell and then computed the ensemble average of the value (fig. S2).

Using the identity p(K1/2 < [L]) = p(R < 0.5) (Fig. 2), the response distributions were converted to the CDF of the response constant K1/2 as schematically shown in Fig. 2A. The error bar of the estimated p(K1/2 < [L]) was obtained by bootstrapping over single responses (95% CI). The data were fitted by the CDF of the log-normal distribution y(x)=0x1x(2)1/2exp((lnx)2/22)dx by the weighted least square fitting method. The weights were given by the inverse of the width of the 95% CI except the data points of [L] = 0 (no step stimulus) and [L] = [L]sat (saturating stimulus), which were weighted with an arbitrary high value. Extracted parameters and their SE were (, ) = (0.822 0.069,0.51 0.12) for [L]0 = 0 M, (, ) = (1.659 0.039,0.291 0.027) for [L]0 = 2 M, (, ) = (4.715 0.012,0.051 0.006) for [L]0 = 100 M, and (, ) = (5.442 0.014,0.052 0.010) for [L]0 = 200 M.

For MeAsp responses, we considered the following three different types of the MWC model, each of which has different variations in the parameter values of m* and n. Model 1: m* is fixed, but n varies. Model 2: m* varies, but n is fixed. Model 3: both m* and n vary. When the parameters are allowed to vary, we assumed the normal distribution for m*, f(m*m,m2), and the log-normal distribution for n, g(nn,n2). We determined the parameters (m*, n, n) for model 1 by the least square method, using the distribution of kinase activity a0, the dose-response curves, and the cumulative distribution of K1/2 (Fig. 4, C to E). The obtained values were (m*, n, n) = (0.445,2.018,0.387). For model 2, both the mean values of m* and n were fixed to the same values as the means of those of model 1, m* = 0.445 and n = 8.1. The SD of m*, m, was chosen to minimize the mean squared error in fitting to the distribution of kinase activity a0, which gave m = 0.02. For model 3, all the parameter values were determined in the same way as model 1. The obtained parameter values were (m, m, n, n) = (0.446,0.010,2.035,0.385), and the correlation coefficient between m* and log(n) was 0.144. For serine responses, we considered only variation in n (model 1). The best-fit parameter values were (m*, n, n) = (0.4838,2.322,0.4174). In fig. S9 (A to D), model 1 was fitted to the data, allowing the log-normal distribution of n to depend on different background conditions, i.e., the parameters m*, n,0, n,0, n,100, n,100, n,200, and n,200 were estimated simultaneously, where the numbers in the subscript indicate the corresponding background MeAsp concentrations. The estimated parameters were m* = 0.455 (0.447 to 0.464), n,0 = 2.030 (1.950 to 2.148), n,0 = 0.409 (0.254 to 0.557), n,100 = 2.206 (2.048 to 2.323), n,100 = 0.426 (0.264 to 0.670), n,200 = 2.057 (1.896 to 2.171), and n,200 = 0.603 (0.449 to 0.872), where the maximum likelihood values and 95% CIs (shown in the parentheses) were obtained from the likelihood function estimated by the Metropolis-Hastings sampling method. The log likelihood function was defined as logL=2Nai=1Na(xii())22i21Ndj=1Nd(xjj())22j21NKk=1NK(xkk())22k2+C, where Na, Nd, and NK are the numbers of data points of the kinase activity distribution (Fig. 4C), the dose-response curves (Fig. 4D), and the CDF of K1/2 (Fig. 3B), respectively; x and are the data point and its uncertainty (SD estimated as 68% CI); () is model prediction; and C is the normalization constant of the likelihood function (which need not be specified for Metropolis-Hastings sampling). The weights in front of the summations were chosen such that it computes the average value of the residuals in each experiment, which gives more equal weight across experiments that might have different statistical power, and that the two datasets (i.e., one that gives the kinase activity distribution and one that gives both the dose-response curves and the CDF of K1/2) have an equal weight.

Acknowledgments: We thank S. Parkinson and V. Sourjik for strains; N. Frankel, A. Waite, and Y. Dufour for help with the microfluidics; S. Boskamp and Z. Rychanavska for cell culture and technical assistance; M. Kamp for microscopy assistance; E. Clay, B. Ait Said, and M. Konijnenburg for software and electronic support; F. Avgidis and S. Grannetia for help with experiments; and H. Mattingly and J. van Zon for discussions and critical reading of the manuscript. Funding: This study was supported by the Allen Distinguished Investigator Program (grant 11562) through the Paul G. Allen Frontiers Group, NIH award R01GM106189, NWO VIDI award 680-47-515, and NWO/FOM Projectruimte grant 11PR2958. Author contributions: K.K., T.E., and T.S.S. designed the research. T.E. and T.S.S. supervised the project and secured funding. K.K., J.M.K., T.E., and T.S.S. conceived the method. K.K. performed the experiments. K.K., T.E., and T.S.S. performed the data analysis and mathematical modeling. K.K. and J.L. performed theoretical analyses in the Supplementary Materials. K.K., J.M.K., T.E., and T.S.S. wrote the manuscript with input from J.L. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Continue reading here:
Adaptive tuning of cell sensory diversity without changes in gene expression - Science Advances

Insights & Outcomes: Cellular bet hedgers and a message from a magnetar – Yale News

This month, Insights & Outcomes is mindful of the mental health implications of COVID-19, the moments when cells act like portfolio managers, and a missive from a Milky Way magnetar.

As always, you can find more science and medicine research news on YaleNews Science & Technology and Health & Medicinepages.

Magnetars, a type of neutron star believed to have an extremely powerful magnetic field, could be the source of some fast radio bursts (FRBs), according to a new study in the journal Nature. FRBs are extremely bright, fast radio emissions that can release more energy in a fraction of a second than the Sun generates over many years. Astronomers discovered the existence of FRBs a decade ago and continue to debate the cause of the signals.

This is the first evidence of an astrophysical source for one FRB, tying it to a galactic neutron star with a large magnetic field and providing evidence that at least some FRBs are consistent with extragalactic magnetars, based on the brightness of this event, said co-author Laura Newburgh, an assistant professor of physics at Yale. Newburgh developed new analysis and measurement information that helped establish the brightness of an FRB emanating from a nearby magnetar located in the Milky Way. The Canadian Hydrogen Intensity Mapping Experiment, a collaboration of 50 scientists, produced the research.

Age, sex, and underlying medical issues have been recognized as major risk factors for an adverse outcome from COVID-19 infection. Now Yale psychiatrists say doctors should also consider another factor that increases risk of death in the pandemic a patients mental health. A new study shows that patients with psychiatric disorders admitted to Yale New Haven Hospital for treatment of COVID-19 were significantly more likely to die than those without a diagnosed mental health disorder. The higher mortality rate held even after controlling for other risk factors such age, sex of the patient, and pre-existing health conditions. The authors theorized that psychiatric disorders such as depression may have a harmful effect on patients immune system response to infection. We need to consider the health of the mind as well as the body when considering treatment options for people diagnosed with COVID-19, said John Krystal, chair of the Department of Psychiatry and senior author of the study. Luming Li, assistant professor of psychiatry, was lead author of the study published in thejournal JAMA Network Open.

In times of stability, cell populations act like investors with large portfolios. They hedge their bets by diversifying receptors on the surfaces of individual cells, preparing the population for sudden swings in the environment. But how can these populations respond quickly to unanticipated changes when the process that dictates composition of those receptors the regulating activity of genes is typically so time consuming?

A new study of E. coli bacteria by Yale scientists shows that when receiving new environmental signals, the diversity of cellular portfolios is reduced 10-fold, allowing the cell population to adjust to changing circumstances.

Essentially, cells instantly stopped hedging their bets and adjusted their sensitivity to focus on following the present signal, effectively consolidating assets into a winning portfolio. The mechanism we found enables a population to very rapidly switch from a bet-hedging mode to an exploitation mode, said Yales Thierry Emonet,professor of molecular, cellular, and developmental biology and of physicsand co-senior author of the study. Before this study, all mechanisms reported to do so also involved gene expression, which is orders of magnitude slower.Keita Kamino is first author of the study, published in the journal Science Advances. The research was conducted in the labs of Emonet and co-senior author Thomas S. Shimizu, group leader at the AMOLF Institute.

Sidi Chen,assistant professor in the Department of Genetics and the Systems Biology Institute and member of the Yale Cancer Center, received a $50,000 research grant from the Alliance for Cancer Gene Therapy (ACGT) to advance a versatile, scalable technology for targeting difficult-to-treat cancers. The technology Chen developed is called MAEGI Multiplexed Activation of Endogenous Genes as an Immunotherapy which leveragesthe natural power of the immune system to fight tumors.

The ACGT Scientific Advisory Council finds Dr. Chens MAEGI technology to be unique and exciting because it simultaneously targets multiple differences and activates multiple immune system responses, said Kevin Honeycutt, CEO and president of ACGT. It has proven to be very effective in animal models. We believe our support will enable its advancement into the clinic where it would have major, life-saving impact on pancreatic and other difficult-to-treat cancers, such as melanoma, glioblastoma and triple negative breast cancer.

Continued here:
Insights & Outcomes: Cellular bet hedgers and a message from a magnetar - Yale News